Home › Companies › BEAM THERAPEUTICS INC. › 2023-2024
Compiled from SEC Form N-PX filings and BEAM THERAPEUTICS INC.’s Form 8-K, filed 2024-06-10 (Item 5.07 on EDGAR). Page generated 02 October 2026.
Explore BEAM THERAPEUTICS INC. in the interactive database Compare manager voting policies
These tallies are BEAM THERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2024-06-10 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Outcome |
|---|---|---|---|---|---|---|
| Elect Director: Graham Cooper | 49,482,793 | 6,520,772 | 1,838,647 | -- | 8,424,668 | Majority: yes |
| Proposal 2: The appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the Company's fiscal year ending December 31, 2024 was ratified, based on the following votes: | 66,048,930 | 176,166 | 41,784 | -- | -- | Majority: yes |
| Proposal 3: The compensation of the Company's named executive officers was approved, on an advisory basis, based on the following votes: | 56,501,513 | 1,295,311 | 45,388 | -- | 8,424,668 | Majority: yes |
This meeting is also recorded here as 2024-06-06; both records come from the same filing, so the date should be checked against it.
Source: BEAM THERAPEUTICS INC., Form 8-K, filed with the SEC on 2024-06-10 — read the filing on EDGAR.
Each item below shows how the 265 asset managers that disclosed a BEAM THERAPEUTICS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 10 wordings of this item as funds reported it.
98% Majority: yes · of votes cast
BEAM THERAPEUTICS INC.’s own tally for this item (“Proposal 3: The compensation of the Company's named executive officers was approved, on an advisory basis, based on the following votes:”): 56,501,513 for, 1,295,311 against, per its Form 8-K filed 2024-06-10 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 82,280,827 outstanding shares: 69% for, 2% against (70% of the company cast a for/against vote).
The 263 asset managers below cast 99% of the shares they voted on this item FOR (55,377,321 for, 666,341 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 7,685,106 | 0 | 0 | 0 | For |
| ARK ETF Trust | 7,681,910 | 0 | 0 | 0 | For |
| Fidelity | 5,820,062 | 0 | 0 | 0 | For |
| ARCH Venture Management, LLC | 5,443,039 | 0 | 0 | 0 | For |
| BlackRock | 3,950,603 | 20,873 | 0 | 0 | For |
| FARALLON CAPITAL MANAGEMENT LLC | 3,516,479 | 0 | 0 | 0 | For |
| State Street | 3,446,189 | 30,366 | 0 | 0 | For |
| T. Rowe Price | 2,278,666 | 0 | 0 | 0 | For |
| Nikko Asset Management Americas, Inc. | 2,028,101 | 0 | 0 | 0 | For |
| Redmile Group, LLC | 1,879,617 | 0 | 0 | 0 | For |
| Temasek Holdings (Private) Ltd | 1,812,972 | 0 | 0 | 0 | For |
| Charles Schwab | 1,160,989 | 0 | 0 | 0 | For |
| Impresa Management LLC | 1,139,443 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 872,600 | 0 | 0 | 0 | For |
| Yiheng Capital Management, L.P. | 505,100 | 0 | 0 | 0 | For |
| BAILLIE GIFFORD & CO LTD | 446,964 | 0 | 0 | 0 | For |
| JPMorgan | 421,711 | 0 | 0 | 0 | For |
| Northern Trust | 404,197 | 49 | 0 | 0 | For |
| Nikko Asset Management Co., Ltd. | 329,950 | 0 | 0 | 0 | For |
| PICTET ASSET MANAGEMENT SA | 273,115 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 211,109 | 0 | 0 | 0 | For |
| MELLON INVESTMENTS Corp | 190,474 | 0 | 0 | 0 | For |
| Goldman Sachs | 184,024 | 0 | 0 | 0 | For |
| Nuveen | 174,191 | 0 | 0 | 0 | For |
| TIAA | 172,527 | 0 | 0 | 0 | For |
Showing the 25 largest of 263 asset managers. See all 263 in the interactive database.
Combines 4 wordings of this item as funds reported it.
88% Majority: yes · of votes cast
BEAM THERAPEUTICS INC.’s own tally for this item (“Elect Director: Graham Cooper”): 49,482,793 for, 6,520,772 against, per its Form 8-K filed 2024-06-10 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 82,280,827 outstanding shares: 60% for, 8% against (68% of the company cast a for/against vote).
The 63 asset managers below cast 96% of the shares they voted on this item FOR (23,694,238 for, 1,048,788 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| ARK ETF Trust | 7,681,910 | 0 | 0 | 0 | For |
| Vanguard | 7,487,514 | 0 | 0 | 0 | For |
| Fidelity | 2,759,135 | 0 | 0 | 0 | For |
| BlackRock | 1,804,526 | 0 | 0 | 0 | For |
| State Street | 1,164,068 | 16,888 | 0 | 0 | For |
| T. Rowe Price | 1,005,154 | 0 | 0 | 0 | For |
| Charles Schwab | 580,439 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 211,109 | 0 | 0 | 0 | For |
| TIAA | 172,527 | 0 | 0 | 0 | For |
| Global X | 155,404 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 0 | 139,813 | 0 | 0 | Against |
| OLD WESTBURY FUNDS INC | 0 | 129,469 | 0 | 0 | Against |
| First Trust | 0 | 118,821 | 0 | 0 | Against |
| Equitable | 28,330 | 85,310 | 0 | 0 | Against |
| AMERICAN BEACON FUNDS | 111,525 | 0 | 0 | 0 | For |
| Dimensional | 0 | 100,098 | 0 | 0 | Against |
| Russell Investments | 95,459 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 85,199 | 0 | 0 | 0 | For |
| Goldman Sachs | 0 | 79,885 | 0 | 0 | Against |
| American Century | 0 | 74,299 | 0 | 0 | Against |
| Lincoln Financial | 59,800 | 5,835 | 0 | 0 | For |
| John Hancock | 36,100 | 27,300 | 0 | 0 | For |
| ProShares | 0 | 54,921 | 0 | 0 | Against |
| Pacific Life | 50,287 | 0 | 0 | 0 | For |
| Morgan Stanley | 46,530 | 0 | 0 | 0 | For |
Showing the 25 largest of 63 asset managers. See all 63 in the interactive database.
Combines 3 wordings of this item as funds reported it.
99.7% Majority: yes · of votes cast
BEAM THERAPEUTICS INC.’s own tally for this item (“Proposal 2: The appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the Company's fiscal year ending December 31, 2024 was ratified, based on the following votes:”): 66,048,930 for, 176,166 against, per its Form 8-K filed 2024-06-10 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 82,280,827 outstanding shares: 80% for, 0.3% against (80% of the company cast a for/against vote).
The 63 asset managers below cast 100% of the shares they voted on this item FOR (24,743,026 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| ARK ETF Trust | 7,681,910 | 0 | 0 | 0 | For |
| Vanguard | 7,487,514 | 0 | 0 | 0 | For |
| Fidelity | 2,759,135 | 0 | 0 | 0 | For |
| BlackRock | 1,804,526 | 0 | 0 | 0 | For |
| State Street | 1,180,956 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,005,154 | 0 | 0 | 0 | For |
| Charles Schwab | 580,439 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 211,109 | 0 | 0 | 0 | For |
| TIAA | 172,527 | 0 | 0 | 0 | For |
| Global X | 155,404 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 139,813 | 0 | 0 | 0 | For |
| OLD WESTBURY FUNDS INC | 129,469 | 0 | 0 | 0 | For |
| First Trust | 118,821 | 0 | 0 | 0 | For |
| Equitable | 113,640 | 0 | 0 | 0 | For |
| AMERICAN BEACON FUNDS | 111,525 | 0 | 0 | 0 | For |
| Dimensional | 100,098 | 0 | 0 | 0 | For |
| Russell Investments | 95,459 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 85,199 | 0 | 0 | 0 | For |
| Goldman Sachs | 79,885 | 0 | 0 | 0 | For |
| American Century | 74,299 | 0 | 0 | 0 | For |
| Lincoln Financial | 65,635 | 0 | 0 | 0 | For |
| John Hancock | 63,400 | 0 | 0 | 0 | For |
| ProShares | 54,921 | 0 | 0 | 0 | For |
| Pacific Life | 50,287 | 0 | 0 | 0 | For |
| Morgan Stanley | 46,530 | 0 | 0 | 0 | For |
Showing the 25 largest of 63 asset managers. See all 63 in the interactive database.
Ranked by the number of BEAM THERAPEUTICS INC. shares each manager voted on the most widely held ballot item of the 2023-2024 meeting, shown as a share of the 82,280,827 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 9.34% |
| 2 | ARK ETF Trust | 9.34% |
| 3 | Fidelity | 7.07% |
| 4 | ARCH Venture Management, LLC | 6.62% |
| 5 | BlackRock | 4.83% |
| 6 | FARALLON CAPITAL MANAGEMENT LLC | 4.27% |
| 7 | State Street | 4.23% |
| 8 | T. Rowe Price | 2.77% |
| 9 | Nikko Asset Management Americas, Inc. | 2.46% |
| 10 | Redmile Group, LLC | 2.28% |
Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).
| Holder | % outstanding | Disclosure |
|---|---|---|
| FMR (Fidelity) | 14.21% | 13F |
| ARK Investment Management LLC | 11.42% | 13G |
| Vanguard Group | 11.24% | 13F |
| FMR LLC and affiliates | 10.88% | DEF14A |
| BlackRock | 9.90% | 13F |
| Funds affiliated with ARCH Venture Partners | 6.62% | DEF14A |
| Farallon Capital Partners and affiliates | 4.99% | DEF14A |
| State Street | 4.53% | 13F |
| John Evans | 2.16% | DEF14A |
| Geode Capital | 1.99% | 13F |
Percentages above are of 82,280,827 shares outstanding, as reported by BEAM THERAPEUTICS INC. on its Form 10-Q dated 2024-03-31 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from BEAM THERAPEUTICS INC.’s 10-Q dated 2024-03-31. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.
At BEAM THERAPEUTICS INC.'s shareholder meeting held 2024-06-05, in the 2023-2024 proxy season, 265 asset managers reported how they voted on 3 ballot items in their SEC Form N-PX filings, covering 1,025 separate fund positions. On the most widely held item on that ballot — Approve, on an advisory basis, the compensation of our named executive officers. — FOR was 98% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: BEAM THERAPEUTICS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2024-06-10.
BEAM THERAPEUTICS INC. proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.